Daanen V, Gastaldo J, Giraud J Y, Fourneret P, Descotes J L, Bolla M, Collomb D, Troccaz J
TIMC Laboratory, Grenoble, France.
Int J Med Robot. 2006 Sep;2(3):256-61. doi: 10.1002/rcs.95.
Prostate brachytherapy consists in placing radioactive seeds for tumour destruction under transrectal ultrasound imaging (TRUS) control. It requires prostate delineation from the images for dose planning. Because ultrasound imaging is patient- and operator-dependent, we have proposed to fuse MRI data to TRUS data to make image processing more reliable. The technical accuracy of this approach has already been evaluated.
We present work in progress concerning the evaluation of the approach from the dosimetry viewpoint. The objective is to determine what impact this system may have on the treatment of the patient. Dose planning is performed from initial TRUS prostate contours and evaluated on contours modified by data fusion.
For the eight patients included, we demonstrate that TRUS prostate volume is most often underestimated and that dose is overestimated in a correlated way. However, dose constraints are still verified for those eight patients.
This confirms our initial hypothesis.
前列腺近距离治疗是在经直肠超声成像（TRUS）引导下植入放射性种子以破坏肿瘤。它需要从图像中勾勒出前列腺轮廓以进行剂量规划。由于超声成像依赖于患者和操作者，我们建议将MRI数据与TRUS数据融合，以使图像处理更可靠。这种方法的技术准确性已经得到评估。
我们展示了从剂量学角度评估该方法的正在进行的工作。目的是确定该系统对患者治疗可能产生的影响。剂量规划从初始的TRUS前列腺轮廓进行，并在通过数据融合修改的轮廓上进行评估。
对于纳入的8名患者，我们证明TRUS前列腺体积最常被低估，并且剂量以相关方式被高估。然而，这8名患者的剂量限制仍然得到验证。
这证实了我们最初的假设。
